Recent research of OviTex® Reinforced Tissue Matrix demonstrated favorable results in various hernia and abdominal wall reconstruction applications

MALVERN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022. The data across these studies demonstrate favorable outcomes with the use of OviTex Reinforced Tissue Matrix that support its use as a better alternative to traditional synthetic and biologic mesh products.

It is estimated that over two million hernia repairs will be performed this year within the United States, Europe, and the United Kingdom. Of critical importance to surgeons and patients is the incorporation of a hernia reinforcement material that will help limit the potential for complications such as infection and hernia recurrence.

Launched in June 2016, OviTex has been rigorously studied in the clinical setting since its commercialization. Recently, two European and four US published clinical studies demonstrated favorable outcomes with the use of OviTex Reinforced Tissue Matrix.1–6 These publications evaluated a total of 280 OviTex patients in both prospective and retrospective studies across a range of patient characteristics, procedural approaches, and planes of placement, including bridged repair. Three studies directly compared OviTex to pure biologics or permanent synthetics, with favorable results for OviTex. These favorable outcomes included lower complication rates and lower recurrence rates for OviTex in comparison to pure biologics1,5, as well as lower surgical site occurrences and similar recurrence rates for OviTex in comparison to permanent synthetics6.

“We are pleased to showcase these six studies,” said Marissa Conrad, Vice President of Clinical Affairs. “As hernia patients become more educated about their treatment options, it’s important they are aware of published research demonstrating that effective, more natural materials are available for their repair.”

Sivaraj, D.; Henn, D.; Fischer, K. S.; Kim, T. S.; Black, C. K.; Lin, J. Q.; Barrera, J. A.; Leeolou, M. C.; Makarewicz, N. S.; Chen, K.; Perrault, D. P.; Gurtner, G. C.; Lee, G. K.; Nazerali, R.* Reinforced Biologic Mesh Reduces Postoperative Complications Compared to Biologic Mesh after Ventral Hernia Repair. Plastic Reconstr Surg - Global Open 2022, 10 (2), e4083. DOI: 10.1097/GOX.0000000000004083

G., 3rd DeNoto.* Bridged Repair of Large Ventral Hernia Defects Using an Ovine Reinforced Biologic: A Case Series. Ann Medicine Surg 2022, 75, 103446. DOI: 10.1016/j.amsu.2022.103446

Timmer, A. S.; Claessen, J. J. M.; Koning, I. M. B. de; Haenen, S. M.; Belt, E. J. T.; Bastiaansen, A.; Verdaasdonk, E. G. G.; Wolffenbuttel, C. P.; Schreurs, W. H.; Draaisma, W. A.; Boermeester, M. A.* Clinical Outcomes of Open Abdominal Wall Reconstruction with the Use of a Polypropylene Reinforced Tissue Matrix: A Multicenter Retrospective Study. Hernia 2022, 26 (5), 1241–1250. DOI: 10.1007/s10029-022-02604-y

DeNoto, G.; Ceppa, E. P.; Pacella, S. J.; Sawyer, M.; Slayden, G.; Takata, M.; Tuma, G.; Yunis, J.* 24-Month Results of the BRAVO Study: A Prospective, Multi-Center Study Evaluating the Clinical Outcomes of a Ventral Hernia Cohort Treated with OviTex® 1S Permanent Reinforced Tissue Matrix. Ann Medicine Surg 2022, 83, 104745. DOI: 10.1016/j.amsu.2022.104745

Goetz, M.; Jurczyk, M.; Junger, H. J.; Brunner, S. M.; Brennfleck, F. W.* Semiresorbable biologic hybrid meshes for ventral abdominal hernia repair in potentially contaminated settings: lower risk of recurrence. Updates Surg. 2022 Dec;74(6):1995-2001. DOI: 10.1007/s13304-022-01378-3

Sivaraj, D.; Fischer, K. S.; Kim, T. S.; Chen, K.; Tigchelaar, S. S.; Trotsyuk, A. A.; Gurtner, G. C.; Lee, G. K.; Henn, D.; Nazerali, R. S.* Outcomes of Biosynthetic and Synthetic Mesh in Ventral Hernia Repair. Plastic Reconstr Surg - Global Open 2022, 10 (12), e4707. DOI: 10.1097/GOX.0000000000004707

*Indicates one or more surgeons are paid consultants of TELA Bio, Inc.

About OviTex OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome. Do not use OviTex in patients known to be sensitive to materials of ovine (sheep) origin. The following adverse events have been reported for surgical repair of hernias (with or without the use of surgical mesh): pain, infection, hernia recurrence, adhesion, bowel obstruction, bleeding, fistula, seroma, perforation, mesh migration, and mesh contraction. For additional important safety information, please see the OviTex Instructions for Use at www.telabio.com/ovitex.html.

About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others, that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data, that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings, and other product defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor Contact Greg Chodaczek 332-895-3230 ir@telabio.com

Media Contact Alyson Kuritz 908-892-7149 alyson@0to5.com

As the Fed raises interest rates, here are the biggest winners and losers from its latest decision.

The market's bubble has now "burst," and will impact "everything everywhere all at once" in the U.S. economy, economists Stephanie Pomboy and Art Laffer argue.

The last few weeks have been rocky, with the collapse of Silicon Valley Bank, and the crypto-heavy Silvergate and Signature banks, dominating the headlines. For a short time, it seemed that the contagion would spread to the global financial giants. Now, however, it appears that we’ve managed to avoid a true banking crisis – and Raymond James’ chief investment officer Larry Adam has pointed out several reasons why. For starters, Adam notes that Credit Suisse, despite its troubles, found a way out

The legendary investor published a chart which quantifies the uninsured clients and unrealized capital losses for major regional banks.

The electric vehicle industry's leading manufacturer Tesla has a stranglehold on production and sales of EVs in the US, including electric SUVs. Tesla, the leading producer of electric vehicles in the US with 1.

(Bloomberg) -- A recession is certain and so are rate cuts this year. That’s the message from the bond market metric Federal Reserve Chairman Jerome Powell highlighted a year ago as the best guide to tip-off economic troubles in the US.Most Read from BloombergFinally, a Serious Offer to Take Putin Off Russia’s HandsAckman Warns of Accelerated Deposit Outflows After Fed DecisionBomb Threat Called In to New York Court Where Trump Hearing HeldA New Chapter of Capitalism Emerges From the Banking Cri

Based on the average brokerage recommendation (ABR), NIO Inc. (NIO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Elon Musk on late Monday offered his opinion on what the Federal Reserve should do with its benchmark interest rate. The Fed's FOMC is meeting for two days this week.

Being profitable on paper belies the tough situation for GameStop.

Nvidia ‘s latest rally has the stock less than $10 billion away from passing Berkshire Hathaway to become the fifth largest by market capitalization. At that point Nvidia stock had fallen 62% from the start of 2022 through its low on Oct. 14, leaving it with a market cap of just $279.6 billion, as worries about the chip sector and valuation weighed on the shares. Berkshire, on the other hand, dropped 12% through its own low on Oct. 12, when it was valued at $588.5 billion.

The National Highway Traffic Safety Administration has revealed the root cause of the battery fires that halted Ford F-150 Lightning production.

Wolfe Research analyst Nigel Coe took a look at what GE Aerospace and GE Vernova will be worth on a stand-alone basis. GE Vernova, GE's power generation businesses, are due to be spun out in early 2024.

A "bull case" scenario for the shares of beleaguered First Republic Bank as it considers its options became more difficult on Wednesday after Treasury Secretary Janet Yellen said there is no discussion on insurance for all bank deposits without approval from the U.S. Congress. First Republic, whose shares have lost much of their value since the banking crisis started in the U.S. on March 8, is among banks speaking to peers and investment firms about potential deals in the wake of U.S. regulators' taking over Silicon Valley Bank and Signature Bank following bank runs. Morgan Stanley analyst Manan Gosalia, in a report earlier this week, set a target price of $54 for First Republic shares in a best-case scenario.

Nvidia’s share price has more than doubled over the past six months as it becomes the preferred supplier to both sides of the AI war raging between Google and Microsoft.

(Bloomberg) -- European stocks fell as investors awaited key rates decisions in the region. US equity futures climbed, signaling a recovery following a tumultuous day of losses on Wall Street Wednesday.Most Read from BloombergFinally, a Serious Offer to Take Putin Off Russia’s HandsAckman Warns of Accelerated Deposit Outflows After Fed DecisionBomb Threat Called In to New York Court Where Trump Hearing HeldA New Chapter of Capitalism Emerges From the Banking CrisisStocks Roiled by Fed Day’s Nerv

Before this sale, ARK Invest owned 9.9 million shares of the crypto exchange worth $575 million.

The stock was trading at 7.9 times its fiscal 2023 earnings on Tuesday versus its historical five-year average of 10.7, data on FactSet shows.

Work at home? Work at the office? It makes no difference, according to a Gallup poll.

Canadian Solar (CSIQ) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.